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IKZF1 deletion (ΔIKZF1) is an important predictor of relapse in both childhood and adult B-cell precursor acute
lymphoblastic leukemia (B-ALL). Previously, we revealed that COBL is a hotspot for breakpoints in leukemia and
could promote IKZF1 deletions. Through an international collaboration, we provide a detailed genetic and clinical
picture of B-ALL with COBL rearrangements (COBL-r). Patients with B-ALL and IKZF1 deletion (n = 133) were
included. IKZF1 1-8 were associated with large alterations within chromosome 7: monosomy 7 (18%),2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
cess article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Translational Oncology Vol. 12, No. 5, 2019 IKZF1 Deletions with COBL Breakpoints Lopes et al. 727isochromosome 7q (10%), 7p loss (19%), and interstitial deletions (53%). The latter included COBL-r, which were
found in 12% of the IKZF1 1-8 cohort. Patients with COBL-r are mostly classified as intermediate cytogenetic risk
and frequently harbor ETV6, PAX5, CDKN2A/B deletions. Overall, 56% of breakpoints were located within COBL
intron 5. Cryptic recombination signal sequence motifs were broadly distributed within the sequence of COBL, and
no enrichment for the breakpoint cluster region was found. In summary, a diverse spectrum of alterations
characterizes ΔIKZF1 and they also include deletion breakpoints within COBL. We confirmed that COBL is a
hotspot associated with ΔIKZF1, but these rearrangements are not driven by RAG-mediated recombination.
Translational Oncology (2019) 12, 726–732Pa
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-cell precursor acute lymphoblastic leukemia (B-ALL) comprises
ultiple subtypes defined by structural and numerical chromosomal
terations. These initiating lesions include aneuploidy and chromo-
mal rearrangements, leading to expression of ectopic fusion proteins
d/or to deregulation of gene expression. During the evolution of B-
LL, a series of secondary genomic alterations, such as DNA copy
mber alterations (CNAs) and sequence mutations, usually emerges
]. These secondary events commonly involve deletions of genes that
code regulators of cell-cycle (CDKN2A and CDKN2B) and B-cell
velopment (PAX5 and IKZF1) [2].
IKZF1 deletions occur in ~15% patients with B-ALL and are more
current in the BCR-ABL1 and Philadelphia-like subgroups,
fecting more than 70% and 40% of the patients, respectively [3].
ZF1 is located within chromosome band 7p12 and codifies the
anscription factor IKAROS. It has two main domains: a DNA-
nding zinc finger domain (encoded by exons 4-6) and a zinc finger
merization domain (encoded by exon 8). Some intragenic IKZF1
letions impair its DNA-binding domain resulting in a dominant-
gative effect (e.g. Δ4-7), while deletions of the whole gene (Δ1-8),
well as deletions of exons 1-2 (e.g. Δ2-3) lead to the gene
ploinsufficiency. IKZF1 deletions have been associated with dismal
ognosis in both pediatric and adult B-ALL [4,5], despite the type of
letion [6]. Interestingly, sequencing of IKZF1 breakpoints
ggested that aberrant recombination activating gene (RAG)–
ediated recombination is responsible for these deletions [7]. Due
their clinical relevance, the identification of IKZF1 deletions has
come an essential prognostic biomarker over the last decade.
ence, aiming to detect these deletions, we developed a rapid and
ficient polymerase chain reaction (PCR)–based method [8].
ecently, by delineating the genetic landscape of IKZF1 Δ1-8, we
entified COBL (COBL cordon-bleu WH2 repeat protein) gene as an
iginating hotspot for IKZF1 deletions [9]. Here we established an
ternational collaboration to enable a detailed genetic and clinical
aracterization of B-ALL with COBL rearrangements (COBL-r).st
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This study included 146 patients diagnosed with B-ALL and IKZF1
letions. This patient cohort comprised two independent groups. The
st one included 133 patients with 1) IKZF1 complete deletion, Δ1-8
= 104); or 2) intragenic deletion of IKZF1 including exon 8, Δn-8
= 29). The second group referred to 13 patients already diagnosed
ith IKZF1 deletions and COBL-r at collaborating centers [8–10].tient samples and information were obtained through the cooperative
forts of nine centers worldwide, and the project was conducted in
cordance with the declaration of Helsinki.
etection of IKZF1 Deletions and CNAs
IKZF1 deletions and CNAs in EBF1, JAK2, CDKN2A, CDKN2B,
X5, ETV6, BTG1, RB1, and the pseudoautosomal region 1-PAR1
HOX, CRLF2, C2F2RA, IL3RA, and P2RY8) were determined by
ther multiplex ligation-dependent probe amplification (MLPA), or
gle nucleotide polymorphism (SNP) array analyses. The SALSA
LPA P335-(A3-B2) and/or SALSA MLPA P202-B1 (MRC Holland)
ere used for MLPA experiments, and the data analyses were performed
ing Coffalyser software. The CytoScan HDArray (Affymetrix) assessed
e occurrence of CNAs in the Brazilian (partially), British, and French
horts. Data were analyzed with Chromosome Analysis Suite software,
rsion 3.2 (Applied Biosystems), and the GRCh38/hg38 build of the
uman Genome Assembly.
haracterization of COBL Breakpoints
We developed customized MLPA assays for the screening of CNAs
ithin chromosome 7.The probes’ design and assay conditions have been
eviously described [9]. To validate our SNP array and MLPA findings,
e performed either multiplexed long-distance PCR (M-PCR) or long-
stance inverse (LDI)-PCR. These PCR approaches allowed us to
nfirm COBL-r and to determinate the breakpoints at nucleotide level.
atient Data and Survival Analyses
For the comparison of laboratory and clinical data between
tients with or without COBL-r, we used the Pearson χ2 test.
verall survival (OS) was defined as the time in months from the
te of diagnosis to death or to the last follow-up assessment for
tients alive. Kaplan-Meier method was used to estimate OS rates
patients according to COBL status with differences compared by
e log-rank test. Statistical analyses were performed using R
ftware, version 3.5.2, and P values b .05 were considered
atistically significant.
nalysis of Activation-Induced Deaminase (AID) or RAG
ecognition Signal Sequences in Recombined COBL Alleles
An agnostic search for motifs located within fragments spanning
bp from the breakpoint junctions of COBL-r was performed using
EME. The limit of output motifs was set to 5, and width ranged
om 2 to 15 bp. The FIMO (Find Individual Motif Occurrences)
ol was used for the analysis of WGCW and CG sequences, and the
combination signal sequence (RSS) consensus sequence was used to
arch for cryptic RSS sequences [11,12].
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Figure 1. Genetic alterations associated with IKZF1 deletions in B-ALL. (A) Patients with IKZF1 deletions spanning its exon 8 presented
four types of aberrations on chromosome 7: monosomy 7; isochromosome 7q, i(7q); 7p loss; and interstitial deletions within 7p arm.
*One cohort of 17 cases comprising only complete deletions of IKZF1 was excluded from this analysis because they would lead to a
biased estimative of CNAs' frequencies among patients with IKZF1 deletions overall. Then, patients were divided into two groups: (B)
intragenic deletions of IKZF1 spanning its exon 8 (n = 29) and (C) complete deletions of IKZF1 (n = 104). (D) The COBL rearrangements
were identified in 25 patients. Most of the deletions spanned between IKZF1 exon 1 and COBL intron 5, although they presented variable
size. (E) These patients had additional alterations, such as ETV6, PAX5, CDKN2A, and CDKN2B deletions.NA, not available. (F) Distribution
of molecular subtypes of B-ALL among patients with or without COBL-r. Legend colors illustrate alterations associated with high risk (red),
intermediate risk (blue), and good risk (green). HH, high hyperdiploidy. (G) The frequency of deletions in genes associated with B-ALL was
compared according to COBL status. PAX5, CDKN2A, CDKN2B, and ETV6 deletions were recurrently observed; however, the frequency of
these CNAs was similar for all these genes, as indicated by P values above each bar. PAR1, pseudoautosomal region 1. (H) No significant
difference was observed when comparing the overall survival of B-ALL patients with COBL-r vs. COBL wild type (P = .65).
728 IKZF1 Deletions with COBL Breakpoints Lopes et al. Translational Oncology Vol. 12, No. 5, 2019esults
ost of the deletions encompassing IKZF1 exon 8 were classified as
hole-gene deletions (Δ1-8: 78% vs. Δn-8: 22%). The CNAs found
the cohort were associated with monosomy 7 (14%; n = 16);
ochromosome 7q (6%; n = 7): 7p loss (15%; n = 17), and
terstitial deletions within 7p (66%; n = 76) (Figure 1A). Among
e Δn-8 group, most of the alterations (93%) were IKZF1 deletions
tectable by the M-PCR, i.e., Δ2-8 or Δ4-8 (Figure 1B).
lternatively, 47% of the Δ1-8 group presented with aberrations
volving loss of the whole 7p, such as monosomy 7 (18%; n = 19),
ochromosome 7q (10%; n = 10), and 7p loss (19%; n = 20). The
maining 55 patients (53%) harbored interstitial deletions; COBL-r
ere found in 12% of the Δ1-8 cohort (Figure 1C).
We identified COBL-r in 25 B-ALL cases with IKZF1 deletions
igure 1D). COBL-r were detected by MLPA screening in 133
tients with B-ALL and IKZF1 deletions (n = 12) or SNP array/
GS investigation performed at collaborating centers (n = 13), asscribed in the methodology. The loss of genes located within 9p
cus — PAX5 (n = 11), CDKN2A (n = 10), and CDKN2B (n = 7)
and ETV6 deletions (n = 10) were the most recurrent additional
terations among these patients (Figure 1E). Demographic and
boratory data for the 25 patients with COBL-r showed they
cluded 17 males and 8 females who were mainly children and
olescents (n = 21), with a median age at diagnosis of 5.5 years
ange 1-59 years) and a median white blood cell count of 7.5 × 109/l
ange 1.5-459.6 × 109/l) (Table 1). The patients were treated on
verse therapy protocols (Table 2). Seven patients relapsed within a
edian of 5.5 years (range 1.4-16.3 years), and six of them
perienced isolated disease recurrence in the bone marrow (n = 5)
testes (n = 1). One patient relapsed at both sites: bone marrow and
ntral nervous system. The median follow-up was 5.1 years (range
3-16.3 years), and the five deaths (mainly in patients with early
lapse) occurred at a median 4.2 years (range 0.3-5.5 years)
llowing diagnosis. In addition, the comparison between patients
Table 1. Demographic and Laboratory Characteristics of B-ALL Cases with COBL Rearrangements. *
Patient Age (Years) Gender WBC (×109/l) Blasts at BM 5′ Breakpoint 3′ Breakpoint Detection Method Karyotype
P004 1 F 96.000 95% ELMO1 intron 14 Upstream COBL SNP array 46,XX,+2,t(3;16)(p21;p13),del(4)(q22),−7,
der(12)t(7;12)(q11;p13),−13,+16,−18,−19,+mar1,+mar2
P034 1 M 3.400 98% RAD50 intron 5 COBL intron 5 LDI-PCR NA
P086 1 M 5.000 95% 7pter COBL intron 7 MLPA/LDI-PCR NA
P120 1 F 459.600 80% 7p14 COBL intron 5 SNP array/M-PCR NA
P056 2 F 1.600 98% SPATA intron 1 COBL intron 5 LDI-PCR 46,XX
P122 2 M 13.400 40% 7pter COBL intron 7 MLPA NA
P145 2 F 92.000 98% TCRGC2 intron 1 COBL intron 13 SNP array 47,XX,del(7)(p11),+10,add(12)(p13),del(12)(p11.2)[4]
P022 4 F 7.500 85% 7p12 COBL intron 2-5 MLPA 46,XX
P003 5 M 10.000 95% IKZF1 intron 3 COBL intron 5 SNP array/M-PCR 46,XY
P074 5 M 16.400 78% 7p12.1 COBL intron 5 ‡ LDI-PCR NA
P079 5 F 5.700 88% 7p COBL intron 8-13 MLPA NA
P121 5 F 7.470 50% 7p12.2 COBL intron 5 SNP array/M-PCR NA
P144 5 M 31.000 NA 7p14.2 COBL intron 5 SNP array 47,XY,+X,del(16)(q13),i(17)(q10),
ider(21)(q10)dup(21)(q?)[3]/ 47,idem,add(7)(p1)[3]
P002 6 M 115.000 97% 7p12.2 COBL intron 5 SNP array/M-PCR 46,XY,del(6)(q21q25),der(12)del(12)
(p11p13)t(12;17)(p13;q11),der(17)t(12;17)
P069 10 F 204.000 89% IKZF1 intron 1 COBL intron 5 LDI-PCR NA
P146 11 M 1.500 90% SPATA intron 2 COBL intron 5 SNP array 48,XY,+X,?t(6;20)(p1;q1),?t(7;9)(p1;p2),
i(9)(q10),+12,der(21)dup(21)(q?)[9]
P068 12 M NA NA IKZF1 intron 3 COBL intron 5 RNA-seq/LDI-PCR 48,XY,+X,del(4)(q25),−7,del(9)del(9)
t(4;9)(q25;p13),+21,+mar[cp8]/
P104 13 M 1.680 84% 7p14 COBL intron 5 MLPA 46,XY,del(7)(p14),der(9;12)(q10;q10),+mar[6]
P090 15 M 4.500 83% 7p22 COBL intron 5 MLPA NA
P114 16 M 55.000 45% 7p COBL intron 2-5 MLPA NA
P143 16 M 6.200 96% COBL intron 1 † 7p12.1 SNP array 46,XY,idic(9)(p13)[1]/ 45,idem,−7[3]/
45,idem,add(2)(p25),−7[9]
P147 Adolescent M NA NA SUN3 intron 5 COBL intron 5 NGS NA
P005 21 M 2.820 90% 7pter Upstream COBL SNP array 46,XY,t(9;22)(q34;q11)
P006 38 M 3.040 67% VWC2 intron 3 Upstream COBL SNP array 46,XY
P001 59 M 58.000 75% 7p12 COBL intron 7 § SNP array 45,XY,−7,t(9;22;15)(p24;q11;q21),add(9)(p13)
BM, bone marrow; LDI-PCR, long-distance inverse PCR; M-PCR, multiplex PCR; MLPA, multiplex ligation-dependent probe amplification; NA, not available; WBC, white blood cell count.
* In this case, blast percent was estimated from peripheral blood.
† Patient had COBL rearrangement and 7p12.3::GRB10 intron 5 deletion.
‡ Patient had an inversion within COBL intron 5.
§ Patient had COBL rearrangement and monosomy 7.
Table 2. Clinical Characteristics and Outcome of B-ALL Cases with COBL Rearrangements
Patient Clinical Trial CNS Disease MRD Day 33 MRD Day 78 PR CMR Day 33 Relapse Outcome Follow-Up (Months)
P147 AALL0232_1 NA NA NA NA NA NA NA NA
P068 AALL0331/UKALLR3 No Negative Negative NA Yes BM Dead 45
P034 AIEOP-BFM ALL2000 No Negative Negative Good Yes No 1st CR 96
P022 AIEOP-BFM ALL2000 No Negative Negative Good Yes No 1st CR 79
P114 AIEOP-BFM ALL2000 No NA NA Good Yes NA Dead NA
P120 AIEOP-BFM ALL2000 No Positive Positive Poor No No Dead 4
P104 ALL IC 2009 Yes Negative Negative Good Yes No 1st CR 38
P145 UKALL2003 No Negative Negative NA Yes No 1st CR 105
P146 UKALL2003 No Negative NA NA Yes BM, CNS Dead 66
P144 UKALL97 No NA NA NA Yes No 1st CR 26
P143 UKALL97 No NA NA NA Yes No 1st CR 167
P003 CAALLF01 No Negative NA Good Yes NA 1st CR 4
P079 COALL 05-92 No NA NA NA Yes No 1st CR 161
P086 COALL 06-97 No Negative NA NA Yes Testes 2nd CR 195
P074 COALL 06-97 No Negative NA NA Yes BM 2nd CR 154
P069 COALL 07-03 No Positive NA NA No No 1st CR 123
P004 EORTC 58081 No Negative Negative Good Yes No 1st CR 49
P090 EsPhALL No Positive NA Good Yes Isolated BM Dead 56
P006 FRALLE 93 No Positive Positive Poor Yes Yes Relapse 192
P002 FRALLE BT No Positive Negative Poor Yes No 1st CR 15
P122 GBTLIALL99 No NA NA Good Yes NA Alive NA
P121 GBTLIALL99 No Negative Negative Good Yes No Alive NA
P005 GRAAPH No Positive Positive Not evaluable Yes No 1st CR 27
P056 NA No Positive NA Good Yes BM Lost follow-up 17
P001 NA No Positive NA Good Yes No SCT; alive 9
BM, bone marrow; CNS, central nervous system; CMR, complete morphological remission; MRD, minimal residual disease; NA, not available; PR, prednisone response; SCT, stem-cell transplantation;
WBC, white blood cell count. MRD-negative status was defined as b0.01% leukemic cells in bone marrow and peripheral blood.
Translational Oncology Vol. 12, No. 5, 2019 IKZF1 Deletions with COBL Breakpoints Lopes et al. 729
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730 IKZF1 Deletions with COBL Breakpoints Lopes et al. Translational Oncology Vol. 12, No. 5, 2019ith COBL-r vs. COBL wild-type revealed that both groups presented
milar laboratory and clinical characteristics (Table 3). Among the B-
LL cytogenetic abnormalities, TCF3-PBX1 and ETV6-RUNX1
ere exclusively found in patients without or with COBL-r,
spectively (Figure 1F). Although we did not observe any significant
fference in the frequency of additional gene deletions when
mparing patients with vs. without COBL-r, it is worthy of note that
DKN2A, ETV6, and PAX5 deletions were more frequent in
tients with COBL-r (Figure 1G). Follow-up data were available for
1 B-ALL patients with (n = 20) or without COBL-r (n = 91). The
S of patients with COBL-r was similar to those with IKZF1
letion only (hazard ratio, 1.278; 95% CI, 0.35-4.68; P = .646)
igure 1H).
The breakpoints of the COBL-r were determined at nucleotide
vel in 11 of the 25 cases, and 56% of breakpoints were located
ithin COBL intron 5 (Figure 2B). To address the possible causes of
ese breakpoints, we first performed an agnostic motif search. This
alysis identified the motif CASWGTGG (E-value = 0.87) within
l 22 breakpoint sequences of COBL-r (Figure 2A; Supplementary
able S1). CASWGTG is similar to the heptamer of the RAG RSS,
hich is composed of a heptamer (5′-CACAGTG-3′) and a nonamer
′-ACAAAAACC-3′) sequence, interspaced by 12 or 23 random
ucleotides associated to RAG-type rearrangements. Since the
namer was absent in our first analysis, we then investigated the
esence of complete motifs associated with the occurrence of
arrangements in leukemia: cryptic RSS sequence (RAG-type
sions), WGCW (AID-type fusions), and CG sequences. WGCW
d CG sequences were not found; however, we identified cryptic
SS in 5 out of 22 breakpoint regions, although none of them were
anning breakpoints within COBL (Supplementary Table S2).E
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ble 3. Demographic and Laboratory Data of Patients with B-ALL *
COBL Rearrangement P Value
No
n = 121
Yes
n = 25
n (%) n (%)
nder 0.473
Male 48 (39.7) 8 (32.0)
Female 73 (60.3) 17 (68.0)
e at diagnosis 0.701
b1 year 2 (1.7) 0 (0.0)
1-9 years 49 (41.5) 12 (48.0)
≥10 years 67 (56.8) 13 (52.0)
BC (×109/L) 0.948
b50 85 (70.2) 16 (69.6)
≥50 36 (29.8) 7 (30.4)
CI risk 0.797
Standard 69 (58.0) 14 (60.9)
High 50 (42.0) 9 (39.1)
S disease 0.741
No 96 (94.1) 23 (95.8)
Yes 6 (5.9) 1 (4.2)
ednisone response 0.143
Good 66 (91.7) 11 (78.6)
Poor 6 (8.3) 3 (21.4)
lapse 0.607
No 75 (70.8) 13 (65.0)
Yes 31 (29.2) 7 (35.0)
utcome 0.604
Alive 94 (77.7) 20 (83.3)
Dead 27 (22.3) 4 (16.7)
BC, white blood cell count; NCI, National Cancer Institute of US; CNS, central nervous system.
* Pearson χ2 calculation.dditionally, we performed a robust analysis for the identification of
yptic RSSs within the whole sequence of COBL (Figure 2, C-D).
he results revealed a broad distribution of this motif throughout the
ne and no enrichment for the breakpoint cluster located in intron 5
COBL.
iscussion
this study, among the Δn-8 group, the majority of the alterations
ere IKZF1 deletions which had already been detected by the M-
CR method [8]. Since the remaining Δn-8 samples harbored
letions restricted to IKZF1, either they had DNA fusions outside
e breakpoint cluster region of IKZF1 or M-PCR failed to detect
em. Among the Δ1-8 group, COBL-r were found in 12% of the
tients. This result revealed that COBL-r are more frequent among
1-8 but rarely related to Δn-8. Although COBL-r were not detected
ithin the Δn-8 group for the cases included in the current proposal,
e found these deletions in patients with COBL-r from a previous
udy [9]. These patients had IKZF1-COBL fusions, which involved
ZF1 intron 1 (n = 1) or intron 3 (n = 2) and COBL intron 5.
Confirming the idea that COBL represents a genomic hotspot for
ZF1 deletions in B-ALL [9], we identified COBL-r in 25 B-ALL
ses with IKZF1 deletions. Although either good (ETV6-RUNX1,
gh hyperdiploid) or high-risk (BCR-ABL1) cytogenetic groups have
en observed in some of these patients, most of them had the so-
lled “B-other” subclassification with either normal or other
normal (BCR-JAK2, IGH-EPOR) cytogenetic profile. In the
rrent genetic risk stratification, many cases with COBL-r would
en be classified as intermediate cytogenetic risk. We found that
ese patients also presented other secondary abnormalities com-
only identified in B-ALL, such as PAX5 and CDKN2A/B and
TV6 deletions. This combination is of special interest because these
tients could benefit from the newly proposed combined risk
ratification strategies, such as IKZF1plus or the UKALL-CNA
assifiers [13–15]. Considering that patients with B-ALL share
milar laboratory and clinical characteristics regardless of COBL
volvement, IKZF1 deletions may play a major role on risk
ratification for these patients.
Regarding the breakpoints of the COBL-r, it is remarkable that
% of them were located within COBL intron 5, although this
gion represents only 16% (47,770 out of 300,587 bp) of the entire
ne. Based on this observation, we formulated two hypotheses to
plain the presence of a hotspot for breakpoints within COBL: 1) the
oduction of a truncated COBL protein, encoded by exons 1-5 only,
uld have a role on leukemogenesis, or 2) there is a breakage
echanism involving COBL intron 5, thus enriching this area for
ne rearrangements.
COBL protein has three Wiskott-Aldrich syndrome protein
mology 2 domains for actin binding. It shows substantial
pression in neurons and muscle cells, although levels are low in
ood [16]. COBL functions as an actin nucleator, controlling
uronal morphology and development [17]. Considering that
OBL does not play a direct role in lymphoid development, the
richment of COBL-r in B-ALL is more likely to be related to
echanisms controlling DNA breakage and promotion of genetic
sions.
Usually, genetic rearrangements in lymphoid malignancies are
used by either AID or the RAG complex. Therefore, we searched
r motifs located within the breakpoint junctions of COBL-r, which
uld potentially provide a rational explanation for the observed
ch
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Figure 2. Identification of motifs within the breakpoint sequences. (A) An agnostic motif search using MEME identified the sequence
CASWGTGG (E-value = 0.87) among 22 breakpoint sequences. (B) The map of 19 deletion breakpoints (red triangles) within COBL
revealed a hotspot located at intron 5. Three breakpoints were detected within a downstream region of 7p12.1. The sequences highlight
two breakpoint clusters located at COBL intron 5. The mapped cryptic recombination signal sequences were not statistically significant.
The cryptic recombination signal sequences (cRSS) with a spacer of 12-bp (c) and 23-bp (d) were mapped along COBL gene. The highest
RIC scores represent cRSS (blue dots) associated with RSS functionality. The gray area highlights the COBL intron 5 and breakpoint
cluster regions.
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ring V(D)J recombination, and previous studies have located
yptic RSS immediately internal to the breakpoints of intragenic
letions of IKZF17. Although the mutual motif within sequencesanning the breakpoints was similar to the heptamer sequence, our
sults do not support the idea that aberrant RAG-mediated
combination is the mechanism responsible for IKZF1 and COBL
deletions.
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terstitial deletions within chromosome 7, especially for deletions
cluding the IKZF1 gene. Most of the COBL-r arose within COBL
tron 5, leading to complete deletion of IKZF1; nevertheless, we also
served fusions between both genes. The analysis of the breakpoint
quences revealed a common motif resembling the heptamer of
combination signal sequence, but the analysis of the whole
nsensus sequence did not provide evidence for RAG-mediated
combination. Lastly, our study demonstrates that patients with
ZF1 deletions are associated with worse outcome regardless of
OBL-r.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.tranon.2019.02.002.
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